» Articles » PMID: 33204798

Response to Re-challenge of a MEK Inhibitor in a Patient with Recurrent Low-grade Serous Carcinoma of the Peritoneum

Overview
Publisher Elsevier
Date 2020 Nov 18
PMID 33204798
Authors
Affiliations
Soon will be listed here.
Abstract

Low-grade serous carcinoma of the ovary/peritoneum is a rare epithelial cancer subtype characterized by younger age at diagnosis, relative chemoresistance, and prolonged overall survival compared with high-grade serous carcinoma. In addition, alterations in the mitogen activated protein kinase pathway are frequent and play a major role in the pathogenesis of this tumor. MEK inhibitors have demonstrated promising activity in the treatment of recurrent low-grade serous carcinoma. Although prevailing wisdom in cancer therapy is that the re-treatment with a drug after emergence of resistance is futile, we report the initial case of a patient with recurrent low-grade serous carcinoma who experienced a partial response when re-challenged with a MEK inhibitor after previously having prolonged stable disease followed by disease progression on a MEK inhibitor.

References
1.
Malpica A, Deavers M, Lu K, Bodurka D, Atkinson E, Gershenson D . Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4):496-504. DOI: 10.1097/00000478-200404000-00009. View

2.
Takekuma M, Wong K, Coleman R . A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. Gynecol Oncol Res Pract. 2016; 3:5. PMC: 4880811. DOI: 10.1186/s40661-016-0026-5. View

3.
Kemper K, de Goeje P, Peeper D, van Amerongen R . Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res. 2014; 74(21):5937-41. DOI: 10.1158/0008-5472.CAN-14-1174. View

4.
Kozar I, Margue C, Rothengatter S, Haan C, Kreis S . Many ways to resistance: How melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer. 2019; 1871(2):313-322. DOI: 10.1016/j.bbcan.2019.02.002. View

5.
Dai B, Meng J, Peyton M, Girard L, Bornmann W, Ji L . STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011; 71(10):3658-68. PMC: 3392199. DOI: 10.1158/0008-5472.CAN-10-3647. View